European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
- PMID: 30803729
- DOI: 10.1016/j.eururo.2019.02.011
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Abstract
Context: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC.
Objective: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable.
Evidence acquisition: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework.
Evidence synthesis: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence.
Conclusions: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019.
Patient summary: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.
Keywords: Diagnosis; European Association of Urology; Follow-up; Guidelines; Management; Medical; Renal cell cancer; Surgery.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
EAU guidelines on renal cell carcinoma: 2014 update.Eur Urol. 2015 May;67(5):913-24. doi: 10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21. Eur Urol. 2015. PMID: 25616710
-
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26. Eur Urol. 2022. PMID: 35346519
-
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update.Eur Urol. 2025 Jun;87(6):683-696. doi: 10.1016/j.eururo.2025.02.020. Epub 2025 Mar 20. Eur Urol. 2025. PMID: 40118739
-
Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel.Eur Urol Oncol. 2020 Aug;3(4):433-452. doi: 10.1016/j.euo.2020.02.001. Epub 2020 Mar 31. Eur Urol Oncol. 2020. PMID: 32245655
-
Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.Eur Urol Oncol. 2020 Feb;3(1):57-72. doi: 10.1016/j.euo.2019.04.005. Epub 2019 Jun 4. Eur Urol Oncol. 2020. PMID: 31171501
Cited by
-
Multimodal ultrasound fusion network for differentiating between benign and malignant solid renal tumors.Front Mol Biosci. 2022 Sep 6;9:982703. doi: 10.3389/fmolb.2022.982703. eCollection 2022. Front Mol Biosci. 2022. PMID: 36148014 Free PMC article.
-
Usefulness of multidetector computed tomography to differentiate between renal cell carcinoma and oncocytoma. A model validation.Br J Radiol. 2020 Nov 1;93(1115):20200064. doi: 10.1259/bjr.20200064. Epub 2020 Aug 26. Br J Radiol. 2020. PMID: 32706993 Free PMC article.
-
Improved Immunotherapy Outcomes via Cuproptosis Upregulation of HLA-DRA Expression: Promoting the Aggregation of CD4+ and CD8+T Lymphocytes in Clear Cell Renal Cell Carcinoma.Pharmaceuticals (Basel). 2024 May 24;17(6):678. doi: 10.3390/ph17060678. Pharmaceuticals (Basel). 2024. PMID: 38931345 Free PMC article.
-
Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.Drug Des Devel Ther. 2020 Sep 28;14:3977-3982. doi: 10.2147/DDDT.S270210. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33061302 Free PMC article. Review.
-
Role of Renal Biopsy in the Management of Renal Cancer: Concordance between Ultrasound/CT-Guided Biopsy Results and Definitive Pathology, Adverse Events, and Complication Rate.J Clin Med. 2023 Dec 20;13(1):31. doi: 10.3390/jcm13010031. J Clin Med. 2023. PMID: 38202038 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical